Brainstem atrophy in dementia with Lewy bodies compared with progressive supranuclear palsy and Parkinson's disease

Sebastian Johannes Müller1, Eya Khadhraoui1, Niels Hansen2

  • 1Institute of Diagnostic and Interventional Neuroradiology, University Medical Center Göttingen (UMG), Georg-August-University Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.

BMC Neurology
|March 22, 2023
PubMed
Abstract

Insights

Dementia with Lewy bodies (DLB) patients show distinct brainstem atrophy patterns. This research helps differentiate DLB from Progressive Supranuclear Palsy (PSP) and Parkinson's disease (PD) using MRI.

Area of Science:

  • Neuroimaging
  • Neurology
  • Radiology

Background:

  • Dementia with Lewy bodies (DLB) is the second most common dementia, yet often underdiagnosed due to overlapping symptoms with Alzheimer's (AD) and Parkinson's disease (PD).
  • Current MRI research often focuses on frontal and temporal lobe atrophy, neglecting brainstem characteristics.
  • Distinguishing DLB from similar conditions like Progressive Supranuclear Palsy (PSP) and PD is crucial for accurate diagnosis and management.

Purpose of the Study:

  • To investigate brainstem atrophy patterns in DLB patients.
  • To identify specific MRI-based biomarkers that differentiate DLB from PSP and PD.
  • To compare manual and automated volumetric analysis methods for assessing brainstem atrophy.

Main Methods:

  • Retrospective analysis of MRI data from 102 patients diagnosed with DLB, PD, PSP, and healthy controls (CTRL).
  • Manual and automated (FastSurfer, FreeSurfer) assessment of brainstem atrophy, including midbrain measurements (diameter, area, volume).
  • Comparison of classical measurement methods and ratios with automated volumetric approaches for diagnostic accuracy.

Main Results:

  • DLB patients exhibited less brainstem atrophy than PSP but more than PD and CTRL groups.
  • Significant differences in midbrain sagittal diameter, area, and volume were observed between DLB, PSP, and PD.
  • Midbrain-to-pons ratios were less effective than absolute measurements for distinguishing PSP from DLB and DLB from PD.

Conclusions:

  • DLB patients demonstrate homogenous brainstem atrophy.
  • Both manual and automated MRI volumetric analyses of the brainstem can effectively distinguish DLB from PSP and PD.
  • Brainstem atrophy patterns represent a valuable tool for differentiating DLB in clinical practice.

Related Concept Videos

Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
634
Brainstem01:19

Brainstem

The brainstem, located inferior to the brain and superior to the spinal cord, serves as a bridge between the cerebrum and the spinal cord. It plays a vital role in relaying information and controlling critical life functions. It comprises three primary regions: the midbrain, pons, and medulla oblongata.
The Midbrain
The midbrain is located beneath the diencephalon and connects the cerebrum with the lower parts of the brain. The cerebral peduncles are prominent midbrain structures that house the...
2.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
562
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
323